Heron Therapeutics, Inc. (HRTX) is a publicly traded Healthcare sector company. As of September 29, 2026, HRTX trades at $0.30 with a market cap of $55.40M and a P/E ratio of -1.76. HRTX moved +5.76% today. Year to date, HRTX is -76.46%; over the trailing twelve months it is -75.91%. Its 52-week range spans $0.26 to $2.68. Analyst consensus is neutral with an average price target of $0.00. Rallies surfaces HRTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Heron Therapeutics signs U.S. multi-product development and license deal with Long Grove Pharmaceuticals: Heron Therapeutics signed a multi-product development and license agreement with Long Grove Pharmaceuticals, covering an exclusive U.S. license and a non-exclusive worldwide manufacturing license. The agreement lasts 10 years from the first commercial sale and automatically renews for two-year periods.
| Metric | Value |
|---|---|
| Price | $0.30 |
| Market Cap | $55.40M |
| P/E Ratio | -1.76 |
| EPS | $-0.18 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.68 |
| 52-Week Low | $0.26 |
| Volume | 3.25M |
| Avg Volume | 0 |
| Revenue (TTM) | $151.18M |
| Net Income | $-34.05M |
| Gross Margin | 70.07% |
2 analysts cover HRTX: 0 strong buy, 0 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $0.00.